 |
Dawning of a New Age in Type 2 Diabetes Care: An Expanding Role for Injectable Agents CME Author Information and Disclosures Release Date: June 30, 2008; Valid for credit through June 30, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Dawning of a New Age in Type 2 Diabetes Care: An Expanding Role for Injectable Agents" symposium held in Washington, DC, on May 14, 2008.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Global Directions in Medicine, Inc. All rights reserved. None of the contents may be reproduced in any form without the prior written permission of Global Directions in Medicine, Inc. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - List psychosocial challenges that may exist in the care of patients with type 2 diabetes.
- Describe strategies to address these psychosocial challenges.
- Review the efficacy, safety, and tolerability of available
injectable agents for the treatment of diabetes.
- Describe how injectable agents can be successfully introduced to patient treatment regimens.
- Describe ways to empower and involve patients in the management of their diabetes.
Authors and Disclosures Luigi Meneghini, MD, MBA
Disclosure:
Grant/Research Support: Merck, Novo Nordisk Inc, sanofi-aventis; Consultant: Medtronic, NIPRO Systems, Novo Nordisk Inc, sanofi-aventis; Speakers' Bureau: Amylin, Eli Lilly, Medtronic, Novo Nordisk Inc, sanofi-aventis Lawrence S. Phillips, MD
Disclosure: Consultant: Merck, Novartis, Novo Nordisk Inc, Pfizer; Takeda; Richard E. Pratley, MD
Disclosure:
Grant/Research Support: GSK, Lilly, Merck, Novartis, Novo Nordisk Inc, Pfizer, Takeda; Consultant: GSK, Novartis, Novo Nordisk Inc, Roche, Takeda; Speakers' Bureau: Merck, Novartis, Novo Nordisk Inc, Takeda Reviewers Linda Graham, RN; Jan Hixon, RN; Trace Hutchison, PharmD Disclosure: The reviewers hereby state that they or their spouse/life partners do not have any
financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity or any amount during the past 12 months. |
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
